This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajamannan, N. M. Articles by Otto, C. M. Search for Related Content PubMed PubMed Citation Articles by Rajamannan, N. M. Articles by Otto, C. M. Related Collections Valvular heart disease Other Treatment Related Article

(Circulation. 2004;110:1180-1182.)
© 2004 American Heart Association, Inc.

Editorial

Targeted Therapy to Prevent Progression of Calcific Aortic Stenosis

Nalini M. Rajamannan, MD; Catherine M. Otto, MD

From the Division of Cardiology, Department of Medicine, Northwestern University (N.M.R.), Chicago, Ill, and Division of Cardiology, Department of Medicine, University of Washington (C.M.O.), Seattle, Wash.

Correspondence to Catherine M. Otto, MD, Professor of Medicine, Division of Cardiology, Box 356422, University of Washington, Seattle, WA 98195-6422. E-mail cmotto{at}u.washington.edu

Key Words: Editorials • stenosis • statins • inhibitors • valves

Calcific aortic valve disease is common, affecting 25% of adults over the age of 65 years, with progression to severe valve obstruction resulting in more than 50 000 aortic valve replacements annually in the United States. "Degenerative" calcific aortic valve disease was thought for many years to be a passive accumulation of calcium binding to the aortic surface of the valve leaflet. Now, convincing data indicate aortic stenosis is an active disease process with a distinctive histological appearance, associated clinical factors, and variable disease progression, which suggests this disease may be amenable to medical therapy to prevent or slow disease progression.

See p 1291

Aortic valve disease is an active cellular process ranging from aortic sclerosis (a process similar to early atherosclerosis) to severe calcification with bone formation and valve obstruction.^1–3 Ex vivo studies have defined the cellular markers and potential signaling pathways important in the progression of this disease. Early valvular sclerotic lesions demonstrate a chronic inflammatory cell infiltrate (macrophages and T lymphocytes), lipid accumulation (apolipoprotein [apo] B, apo(a), and apoE), and -actin-expressing cells in the lesion and adjacent fibrosa. End-stage calcified valves contain mature lamellar bone² with expression of specific bone markers important in the development of osteoblast bone formation.³ In addition, angiotensin-converting enzyme (ACE) and angiotensin II type 1 (AT1) and type 2 (AT2) receptors are present in stenotic aortic valves, implicating this signaling pathway in the disease process.⁴

These observations are analogous to the cellular findings in vascular atherosclerosis and corroborate epidemiological studies that showed similar associations of clinical risk factors with both atherosclerosis and aortic valve disease.⁵ Our understanding of the biological mechanisms that result in calcification of valve leaflets has led to the hypothesis that targeted drug therapy might prevent slow disease progression. (Figure) Two of the leading candidates for drug therapy are HMG-CoA reductase inhibitors (statins) and ACE inhibitors.

View larger version (68K): [in this window] [in a new window]   Important cellular pathways involved in development of aortic valve calcification, with potential targets for drug therapy outlined in red. ACEI indicates ACE inhibitor.

The hypothesis that lipids contribute to the development of valve calcification and stenosis can be tested in emerging experimental models.^6,7 In addition to a lipid-lowering effect, statins have other beneficial effects in vascular atherosclerosis, including modification of endothelial function, decreased inflammation via inhibition of macrophage activation, upregulation of endothelial nitric oxide synthase (eNOS), and inhibition of smooth muscle cell proliferation.⁸ Experimental models suggest that statins might have similar effects in valve tissue, with demonstration of a decrease in atherosclerotic effects, a reduction in osteoblast gene markers, and inhibition of calcification via upregulation of eNOS.⁹ Although laboratory models allow detailed evaluation of the effects of blocking these pathways in a controlled setting, determination of the long-term clinical effects of targeted medical therapy, in the milieu of the other clinical and genetic factors that may affect disease progression and clinical outcome, requires evaluation in patients with calcific valve disease.

In this issue of Circulation, Rosenhek and colleagues¹⁰ evaluate the effects of statin therapy in a retrospective study of 211 adults with varying degrees of aortic stenosis. The data convincingly demonstrate a significantly lower rate of disease progression in those treated with a statin compared with those not taking statin therapy. The magnitude of the effect of therapy is similar to that in previous studies, with all showing an 50% annual reduction in measurable disease progression, whether quantified by Doppler echocardiographic jet velocity or valve area or by electron-beam tomographic valve calcium scores (Table).^11–15 One unique aspect of the present study is the inclusion of patients with severe stenosis and the demonstration that disease progression is reduced across the range of disease severity. Although encouraging, this is a somewhat surprising finding given the extensive valve calcification seen in end-stage disease, a process that appears less amenable to intervention than the early valve lesion.

View this table: [in this window] [in a new window]   Nonrandomized Retrospective Studies of Medical Therapy to Prevent Progression of Calcific Aortic Stenosis

The mechanism of the effect of statins on the disease process in the aortic valve remains unclear. The rate of disease progression was linked to serum LDL levels in only 2 of these 6 studies.^11,14 The others postulate that the discordance between disease progression and serum lipid levels indicates that antiinflammatory effects of statins are more important than lipid-lowering effects in calcific valve disease. Clarification of the mechanism of the association between statin therapy and the rate of disease progression will be crucial to effectively tailor therapy for this disease process.

The study by Rosenhek et al¹⁰ also is the first large series to evaluate the effect of ACE inhibitor therapy on aortic stenosis progression. ACE inhibitors interfere with the renin-angiotensin system and exert beneficial actions on vascular tissues beyond their blood pressure-lowering effects. ACE inhibitors reduce atherogenesis in experimental models both by inhibiting the conversion of inactive angiotensin I to active angiotensin II and by decreasing bradykinin levels, which in turn releases nitric oxide, resulting in improved endothelial function and a decrease in smooth muscle cell proliferation.¹⁶

In the study by Rosenhek et al,¹⁰ there was no significant difference in disease progression in patients taking ACE inhibitor therapy compared with those not taking an ACE inhibitor, despite careful consideration of the effects of coexisting hypertension. Although these data are discouraging, it would be appropriate to evaluate ACE inhibitor therapy in other retrospective databases and in animal models before concluding this therapy is ineffective. Hemodynamic effects of ACE inhibitors might obscure the effects at the tissue level by changing the flow conditions across the valve.¹⁷ Other considerations include the relative tissue effects of different ACE inhibitors, timing of therapy in the disease process, and the sample size needed to demonstrate an effect that may be clinically significant over a longer follow-up interval. In addition, ACE inhibitors might impact long-term clinical outcome by other mechanisms, for example, by modulation of the left ventricular response to chronic pressure overload.¹⁸ In any case, the observation that 63% of these consecutive patients with aortic stenosis were already taking ACE inhibitor therapy has significant implications for design of future clinical trials.

We are making progress toward medical therapy for calcific valve disease, but the studies to date are not ideal. All of these publications are based on nonrandomized, retrospective databases, which have many well-known limitations. However, the impressively lower rate of disease progression in patients taking statin therapy in 6 different databases, even with these small, possibly biased patient groups, provides compelling justification for further investigation of this potential therapy. Ultimate proof of the efficacy of statin therapy in adults with aortic stenosis will depend on prospective clinical trials; these retrospective studies establish an association but not a cause-and-effect relationship.

At least 2 prospective, randomized, placebo-controlled multicenter studies of lipid-lowering therapy to prevent disease progression in aortic stenosis are in progress: the Aortic Stenosis Progression Observation: Measuring Effect of Rosuvastatin (ASTRONOMER) study in Canada and the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) study in Europe (personal communication from K.L. Chan, 2004; and Rossebo et al¹⁹). We should await the results of these trials to determine whether it will become appropriate to prescribe statin therapy routinely in patients with calcific valve disease.

We also need to keep an open mind about what therapies might be most effective for calcific valve disease. Inhibition of lipid accumulation and the effects of ACE inhibitors in the valve tissue are the first pathways to be studied; however, other more specific therapies targeting endothelial disruption, inflammation, or tissue calcification may be more effective. Therapy may need to be tailored to the stage of the disease process; some interventions may prevent initiation of the disease process, whereas others may be more effective in slowing calcium accumulation in end-stage disease. Experimental models are critical to define the disease process and timing of therapy and for development of future clinical trials for aortic valve disease. In the meanwhile, we should continue to evaluate cardiac risk profiles in all our patients, particularly those with calcific valve disease, and institute appropriate primary and secondary preventative measures in accordance with national and international clinical guidelines.

Disclosure

Dr Rajamannan is an inventor on a patent assigned to the Mayo Clinic titled "Method for Slowing Heart Valve Degeneration." Dr Otto is coinventor on a patent application by the University of Washington titled "Methods of Inhibition of Stenosis and Sclerosis of the Aortic Valve." Dr Otto has formally relinquished all financial interest in the patent.

Footnotes

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

1. O’Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb. 1996; 16: 523–532.[Abstract/Free Full Text]
   
2. Mohler ER III, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation. 2001; 103: 1522–1528.[Abstract/Free Full Text]
   
3. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003; 107: 2181–2184.[Abstract/Free Full Text]
   
4. O’Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002; 106: 2224–2230.[Abstract/Free Full Text]
   
5. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997; 29: 630–634.[Abstract]
   
6. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002; 105: 2660–2665.[Abstract/Free Full Text]
   
7. Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003; 41: 1211–1217.[Abstract/Free Full Text]
   
8. Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003; 5: 372–378.[Medline] [Order article via Infotrieve]
   
9. Rajamannan NM, Subramaniam M, Springett M, et. al. Atorvastatin inhibits aortic valve calcification in an experimental model of chronic hypercholesterolemia via nonlipid lowering effects. J Am Coll Cardiol. 2003; 41 (suppl A): 842.
   
10. Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110: 1291–1295.[Abstract/Free Full Text]
    
11. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001; 104: 1927–1932.[Abstract/Free Full Text]
    
12. Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002; 359: 1125–1126.[CrossRef][Medline] [Order article via Infotrieve]
    
13. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002; 40: 1723–1730.[Abstract/Free Full Text]
    
14. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001; 88: 693–695.[CrossRef][Medline] [Order article via Infotrieve]
    
15. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001; 104: 2205–2209.[Abstract/Free Full Text]
    
16. Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep. 2002; 4: 363–372.[Medline] [Order article via Infotrieve]
    
17. O’Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004; 52: 185–191.[Medline] [Order article via Infotrieve]
    
18. Routledge HC, Townend JN. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens. 2001; 15: 659–667.[CrossRef][Medline] [Order article via Infotrieve]
    
19. Rossebo A, Pedersen T, Skjaerpe T, et al. Design of the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) Study. Atherosclerosis. 2003; 170 (suppl 4): 253. Abstract.[CrossRef][Medline] [Order article via Infotrieve]
    

Related Article:

Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis

Raphael Rosenhek, Florian Rader, Nicole Loho, Harald Gabriel, Maria Heger, Ursula Klaar, Michael Schemper, Thomas Binder, Gerald Maurer, and Helmut Baumgartner
Circulation 2004 110: 1291-1295. [Abstract] [Full Text]

This article has been cited by other articles:

				2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al. 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, October 7, 2008; 118(15): e523 - e661. [Full Text] [PDF]

				S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]

				K. Arishiro, M. Hoshiga, N. Negoro, D. Jin, S. Takai, M. Miyazaki, T. Ishihara, and T. Hanafusa Angiotensin Receptor-1 Blocker Inhibits Atherosclerotic Changes and Endothelial Disruption of the Aortic Valve in Hypercholesterolemic Rabbits J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1482 - 1489. [Abstract] [Full Text] [PDF]

				R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]

				R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF]

				R. V. Freeman and C. M. Otto Spectrum of Calcific Aortic Valve Disease: Pathogenesis, Disease Progression, and Treatment Strategies Circulation, June 21, 2005; 111(24): 3316 - 3326. [Full Text] [PDF]

				S. Verma, P. E. Szmitko, P. W. M. Fedak, L. Errett, D. A. Latter, and T. E. David Can statin therapy alter the natural history of bicuspid aortic valves? Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2547 - H2549. [Full Text] [PDF]

				H. C. Routledge, J. N. Townend, R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, T. Binder, G. Maurer, et al. Letter Regarding Article by Rosenhek et al, "Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis" * Response Circulation, May 3, 2005; 111(17): e274 - e275. [Full Text] [PDF]

				D. W. Quinn Jr. and S. A. Spinler Efficacy of statins in preventing progression of aortic stenosis Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 979 - 981. [Full Text] [PDF]

				Aortic Stenosis Slowed by Statins -- But Not ACE Inhibitors Journal Watch Cardiology, December 3, 2004; 2004(1203): 6 - 6. [Full Text]

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rajamannan, N. M. Articles by Otto, C. M. Search for Related Content PubMed PubMed Citation Articles by Rajamannan, N. M. Articles by Otto, C. M. Related Collections Valvular heart disease Other Treatment Related Article